Emerging and Evolving Biomarkers: KRAS: Recent Findings, Laboratory Considerations, and Clinical Implications




Speaker:
Craig Mackinnon, MD, PhD

The University of Alabama at Birmingham

Moderator:

Kurtis Davies, PhD
University of Colorado, Anschutz Medical Campus


This webinar is part 7 of the Emerging and Evolving Biomarkers Series

Description:

KRAS plays an important role in regulating cell growth and proliferation. It is commonly mutated in cancer, and recently targeted therapy is available for patients whose tumors harbors specific KRAS variants. This presentation will describe the role of KRAS in cellular signal transduction pathways, discuss different methods for testing KRAS for genetic variants, and review the clinical implications for cancers with KRAS mutation.

Learning Objectives:

  • Describe the KRAS signaling pathway
  • Describe molecular testing methods utilized to detected variants in the KRAS gene
  • Explain the clinical significance of KRAS variants

This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.


Recording Date: October 12, 2021
Duration: 55 min
Level of Instruction: Basic




Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit: December 31, 2022

How to claim credit: 

To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.


AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation